| scholarly article | Q13442814 |
| P50 | author | Xu-Dong Wang | Q56670352 |
| Yonghao Yu | Q90975755 | ||
| Chiho Kim | Q98728928 | ||
| P2860 | cites work | Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway | Q24306635 |
| STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling | Q24336398 | ||
| STING: infection, inflammation and cancer | Q26776009 | ||
| Structural mechanism of cytosolic DNA sensing by cGAS | Q27678393 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma | Q28550512 | ||
| A tissue-specific atlas of mouse protein phosphorylation and expression | Q29616549 | ||
| PARP inhibition: PARP1 and beyond | Q29619617 | ||
| Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. | Q33718199 | ||
| DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity | Q33804663 | ||
| Molecular evolutionary and structural analysis of the cytosolic DNA sensor cGAS and STING | Q33983673 | ||
| Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors | Q34309488 | ||
| Immune surveillance of tumors | Q34579196 | ||
| Evaluating multiplexed quantitative phosphopeptide analysis on a hybrid quadrupole mass filter/linear ion trap/orbitrap mass spectrometer | Q35001243 | ||
| Phosphorylation of CHIP at Ser20 by Cdk5 promotes tAIF-mediated neuronal death | Q36472440 | ||
| STING-cytosolic DNA sensing: the backbone for an effective tumor radiation therapy | Q36540171 | ||
| The anticancer immune response: indispensable for therapeutic success? | Q36677608 | ||
| Inflammation-driven carcinogenesis is mediated through STING | Q37207341 | ||
| Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib | Q37623863 | ||
| New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs | Q38020082 | ||
| Innate immune sensing and signaling of cytosolic nucleic acids | Q38198154 | ||
| Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors | Q38262230 | ||
| Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing | Q38959510 | ||
| A Strategy to Combine Sample Multiplexing with Targeted Proteomics Assays for High-Throughput Protein Signature Characterization | Q39033381 | ||
| PARP inhibitors: Synthetic lethality in the clinic | Q39182835 | ||
| Cyclic GMP-AMP as an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA. | Q39235226 | ||
| The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. | Q39414183 | ||
| Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence. | Q40036388 | ||
| Mitotic progression following DNA damage enables pattern recognition within micronuclei. | Q40036392 | ||
| cGAS surveillance of micronuclei links genome instability to innate immunity | Q41412907 | ||
| BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. | Q43755302 | ||
| Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome | Q45389826 | ||
| Cytoplasmic chromatin triggers inflammation in senescence and cancer | Q46165767 | ||
| Proteomic Analysis of the Downstream Signaling Network of PARP1. | Q48254511 | ||
| Detection of functional protein domains by unbiased genome-wide forward genetic screening. | Q52579509 | ||
| Cytosolic DNA Sensing in Organismal Tumor Control | Q60548668 | ||
| Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors | Q60918179 | ||
| PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer | Q63383798 | ||
| PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness | Q64388718 | ||
| The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer | Q88286449 | ||
| PARP and PARG inhibitors in cancer treatment | Q89581160 | ||
| PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer | Q90251051 | ||
| PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer | Q90428750 | ||
| Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation | Q90975757 | ||
| Structural basis for allosteric PARP-1 retention on DNA breaks | Q91521096 | ||
| Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer | Q91689195 | ||
| Inhibition of cGAS-Mediated Interferon Response Facilitates Transgene Expression | Q91866752 | ||
| DNA sensing by the cGAS-STING pathway in health and disease | Q92267263 | ||
| PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow | Q93078964 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P577 | publication date | 2020-08-26 | |
| P1433 | published in | eLife | Q2000008 |
| P1476 | title | PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response | |
| P478 | volume | 9 |
| Q114870922 | Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment |
| Q104571998 | Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1 |
| Q104500089 | Immunomodulation by targeted anticancer agents |
| Q112643403 | Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells |
Search more.